, NGS : Next generation Sequencing) qui permet de comparer et d'analyser les ARN viraux des différents sous-types

, Tableau 8 : détail de l'organisation des zones à haut risque et à bas risque ainsi que les espaces de passage d'une zone à l'autre

B. N. Fields, D. M. Knipe, B. N. Fields, and D. M. Knipe, chief Bernard N. Fields

D. M. Knipe and .. , XIX-2336-83 p.); ill. 29 cm, vol.2, 1990.

E. Leroy, S. Baize, and J. Gonzalez, Les fièvres hémorragiques à virus Ebola et Marburg : l'actualité des filovirus, 2011.

J. Huraux and F. Barré-sinoussi, , 1947.

. Agence-universitaire-de-la-francophonie, ); ill. en noir et en coul., jaquette ill.; 31 cm; rel, vol.1, 2003.

D. M. Knipe, P. M. Howley, . Fields, and . Virology, , 2007.

A. Mammette, Virologie médicale / A. Mammette

, ); ill. 24 cm; br. (Collection Azay (Lyon)), vol.1, 2002.

. Disponible,

P. Formenty, C. Hatz, L. Guenno, B. Stoll, A. Rogenmoser et al., Human Infection Due to Ebola Virus, J Infect Dis. 1 févr, vol.179, issue.Supplement_1, pp.48-53, 1999.

H. Fleury, . J. Virologie-humaine-/-h, and .. Fleury,

. Elsevier-masson, XXI-265 p.); ill.cartes, tabl.graph., couv. ill. en coul.; 25 cm; br. (Abrégés. Connaissances et pratique), vol.1, 2009.

, Ebola Virus Disease Distribution Map | Ebola Hemorrhagic Fever | CDC, 2017.

, Outbreaks Chronology: Ebola Virus Disease | Ebola Hemorrhagic Fever | CDC, 2017.

, Médecine & Armées tome, vol.44, issue.2

. Disponible,

A. Negredo, G. Palacios, S. Vázquez-morón, F. González, H. Dopazo et al., Discovery of an Ebolavirus-Like Filovirus in Europe, PLOS Pathog, vol.7, issue.10, p.1002304, 2011.

D. M. Pigott, N. Golding, A. Mylne, Z. Huang, A. J. Henry et al., Mapping the zoonotic niche of Ebola virus disease in Africa, eLife. 8 sept, vol.3, p.4395, 2014.

R. K. Singh, K. Dhama, Y. S. Malik, M. A. Ramakrishnan, K. Karthik et al., Ebola virus-epidemiology, diagnosis, and control: threat to humans, lessons learnt, and preparedness plans-an update on its 40 year's journey, Vet Q. déc, vol.37, issue.1, pp.98-135, 2017.

L. Collier, J. Oxford, J. Pipkin, . Joly-v-;-médecin, J. Pipkin et al., XII-284 p.); ill. en noir et en coul., couv. ill. en coul.; 26 cm; br. (Collection De la biologie à la clinique), vol.1, 1921.

D. Yu, T. Weng, X. Wu, F. Wang, X. Lu et al., The lifecycle of the Ebola virus in host cells, Oncotarget. 15 juin, vol.8, issue.33, pp.55750-55759, 2017.

, L entrée du virus Ébola et Marburg : interaction entre la glycoprotéine virale et les facteurs cellulaires-PDF

L. Virus and E. ,

. Les-crises and . Fr, , 2015.

. Disponible,

, Virus Pathogen Database and Analysis Resource (ViPR)-Filoviridae-Genome database with visualization and analysis tools

I. Messaoudi, G. K. Amarasinghe, and C. F. Basler, Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus, Nat Rev Microbiol, vol.13, issue.11, pp.663-76, 2015.

, Virus Ecology | Ebola Hemorrhagic Fever | CDC

, OMS | Ce que l'on sait à propos de la transmission interhumaine du virus Ebola

, 23. francaise C-R. Guide opérationnel sur la lutte contre Ebola

. Croix-rouge-française,

. Who-|-ebola,

. Disponible,

G. Baize, S. Georges, and A. , Les filovirus. Virologie. 1 mars, vol.11, issue.2, pp.105-125, 2007.

J. Misasi and N. J. Sullivan, Camouflage and Misdirection: The Full-On Assault of Ebola Virus Disease, Cell, vol.159, issue.3, pp.477-86, 2014.

, OMS | Définitions de cas recommandées pour la surveillance des maladies à virus Ebola ou Marburg, p.14, 2017.

, OMS | Définitions de cas recommandées pour la surveillance des maladies à virus Ebola ou Marburg, p.14, 2017.

|. Diagnosis-|-ebola-hemorrhagic-fever and . Cdc, , p.12, 2017.

. Disponible,

Y. Kurosaki, N. Magassouba, O. K. Oloniniyi, M. S. Cherif, S. Sakabe et al., Development and Evaluation of Reverse Transcription-Loop-Mediated Isothermal Amplification (RT-LAMP) Assay Coupled with a Portable Device for Rapid Diagnosis of Ebola Virus Disease in Guinea, PLoS Negl Trop Dis, vol.22, issue.2016, p.14, 2017.

, Swift Analytical | Instruments | Low Volume Liquid Handling and Quantification | DNA, RNA & Proteins

A. , Anses relatif à une « demande d'expertise sur le rôle potentiel des animaux domestiques dans la transmission du virus de la maladie d'Ebola»

. Disponible,

M. J. Broadhurst, J. D. Kelly, A. Miller, A. Semper, D. Bailey et al., ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study, Lancet Lond Engl. 29 août, vol.386, issue.9996, pp.867-74, 2015.

, Ebola : vers un test de diagnostic fiable et rapide [Internet]. lesechos.fr

N. F. Walker, C. S. Brown, D. Youkee, P. Baker, N. Williams et al., Evaluation of a point-of-care blood test for identification of Ebola virus disease at Ebola holding units, Eurosurveillance. 26 mars, vol.20, issue.12, p.21073, 2015.

M. L. Boisen, R. W. Cross, J. N. Hartnett, A. Goba, M. Momoh et al., Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection, J Infect Dis, vol.214, issue.3, pp.203-212, 2016.

. , Validation technique d'un test de diagnostic du virus Ebola en moins de quinze minutes sur le terrain

C. , , 2014.

F. Gallais, F. Gay-andrieu, V. Picot, N. Magassouba, S. Mély et al., Validation sur le terrain du nouveau test de diagnostic rapide Ebola eZYSCREEN®Field assessment of the new rapid diagnostic test Ebola eZYSCREEN®, Bull Société Pathol Exot. 1 févr, vol.110, issue.1, pp.38-48, 2017.

S. L. Bixler, T. M. Bocan, J. Wells, K. Wetzel, S. Van-tongeren et al., Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus

, Antiviral Res, vol.28, issue.2017

. Disponible,

Y. Furuta, B. B. Gowen, K. Takahashi, K. Shiraki, D. F. Smee et al., Favipiravir (T705), a novel viral RNA polymerase inhibitor, Antiviral Res, vol.100, issue.2, 2013.
DOI : 10.1016/j.antiviral.2013.09.015

URL : http://europepmc.org/articles/pmc3880838?pdf=render

L. Oestereich, A. Lüdtke, S. Wurr, T. Rieger, C. Muñoz-fontela et al., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res. 1 mai, vol.105, pp.17-21, 2014.

D. Sissoko, C. Laouenan, E. Folkesson, M. 'lebing, A. Beavogui et al., Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea, PLoS Med, vol.13, issue.3, p.16, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01327168

R. Taylor, P. Kotian, T. Warren, R. Panchal, S. Bavari et al., BCX4430-a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease, J Infect Public Health, vol.9, issue.3, pp.220-226, 2016.

T. Warren, J. Wells, R. Panchal, K. S. Stuthman, N. L. Garza et al., Protection against filovirus disease by a novel broad-spectrum nucleoside analogue BCX4430, 2014.

L. K. Mcmullan, M. Flint, J. Dyall, C. Albariño, G. G. Olinger et al., The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus, Antiviral Res. 1 janv, vol.125, pp.71-79, 2016.

J. Dunning, S. B. Kennedy, A. Antierens, J. Whitehead, I. Ciglenecki et al., Experimental Treatment of Ebola Virus Disease with Brincidofovir, PLOS ONE. 9 sept, vol.11, issue.9, p.162199, 2016.

E. Davidson, C. Bryan, R. H. Fong, T. Barnes, J. M. Pfaff et al., Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies, J Virol. 26 août, vol.89, issue.21, pp.10982-92, 2015.

Y. Zhang, D. Li, J. X. Huang, and Z. , Fighting Ebola with ZMapp: spotlight on plant-made antibody, Sci China Life Sci, vol.57, issue.10, pp.987-995, 2014.

X. Qiu, G. Wong, J. Audet, A. Bello, L. Fernando et al., Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp TM, Nature, vol.514, issue.7520, pp.47-53, 2014.

A. Randomized, Controlled Trial of ZMapp for Ebola Virus Infection, N Engl J Med, vol.375, issue.15, pp.1448-56, 2016.

E. Lutte-contre, Salle de presse | Inserm, résultats encourageants pour l'essai clinique Prévail, 2016.

E. P. Thi, C. E. Mire, A. Lee, J. B. Geisbert, J. Z. Zhou et al., Lipid nanoparticle siRNA treatment of Ebola virus Makona infected nonhuman primates, Nature. 21 mai, vol.521, issue.7552, pp.362-367, 2015.

J. Dunning, F. Sahr, A. Rojek, F. Gannon, G. Carson et al., Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial, PLOS Med. 19 avr, vol.13, issue.4, p.1001997, 2016.

K. Tatiparti, S. Sau, S. K. Kashaw, and A. K. Iyer, siRNA Delivery Strategies: A Comprehensive Review of Recent Developments, Nanomaterials. 5 avr, vol.7, issue.4, p.77, 2017.

P. L. Iversen, T. K. Warren, J. B. Wells, N. L. Garza, D. V. Mourich et al., Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections. Viruses, vol.4, pp.2806-2836, 2012.

A. E. Heald, P. L. Iversen, J. B. Saoud, P. Sazani, J. S. Charleston et al., Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and Marburg Virus: Results of Two Single-Ascending-Dose Studies, Antimicrob Agents Chemother, vol.58, issue.11, pp.6639-6686, 2014.

T. Warren, K. Warfield, J. Wells, D. Swenson, K. Donner et al., Advanced antisense therapies for postexposure protection against lethal filovirus infections, Nat Med. 1 sept, vol.16, pp.991-995, 2010.

, AVI-7537) Drug Therapy (Sarepta Therapeutics) for Treating Ebola Virus Disease, ECRI Institute, vol.6002

M. K. Konde, D. P. Baker, F. A. Traore, M. S. Sow, A. Camara et al., Interferon ?-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-ofconcept trial, PLoS ONE, vol.22, issue.2017, p.15, 2017.

P. Arnaud, Les différents interférons : Pharmacologie, mécanismes d'action, tolérance et effets secondaires, Rev Médecine Interne, vol.23, pp.449-458, 2002.

L. M. Smith, L. E. Hensley, T. W. Geisbert, J. Johnson, A. Stossel et al., Interferon-? Therapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg Hemorrhagic Fever, J Infect Dis. 15 juill, vol.208, issue.2, pp.310-318, 2013.

T. W. Geisbert, L. E. Hensley, P. B. Jahrling, T. Larsen, J. B. Geisbert et al., Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys, The Lancet. 13 déc, vol.362, issue.9400, pp.1953-1961, 2003.

A. Lee and G. P. Vlasuk, Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor, J Intern Med, vol.254, issue.4, pp.313-334, 2003.
DOI : 10.1046/j.1365-2796.2003.01224.x

URL : https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2796.2003.01224.x

. Oms-|-traitements, J. Vaccins-potentiels-contre-le-virus-ebola-;-van-griensven, T. Edwards, X. De-lamballerie, M. G. Semple et al., Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea, N Engl J Med. 7 janv, vol.374, issue.1, pp.33-42, 2016.

S. Sridhar, Clinical development of Ebola vaccines, Ther Adv Vaccines. sept, vol.3, issue.5-6, pp.125-163, 2015.
DOI : 10.1177/2051013615611017

URL : http://journals.sagepub.com/doi/pdf/10.1177/2051013615611017

A. Marzi, P. Halfmann, L. Hill-batorski, F. Feldmann, W. L. Shupert et al., An Ebola whole-virus vaccine is protective in nonhuman primates, Science. 24 avr, vol.348, issue.6233, pp.439-481, 2015.
DOI : 10.1126/science.aaa4919

URL : http://europepmc.org/articles/pmc4565490?pdf=render

A. M. Henao-restrepo, I. M. Longini, M. Egger, N. E. Dean, W. J. Edmunds et al., Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial, The Lancet. 29 août, vol.386, issue.9996, pp.857-66, 2015.

, Préparation contre le risque de nouvelles épidémies d'Ebola : la garantie d'achat de vaccin par Gavi

M. Schweneker, A. S. Laimbacher, G. Zimmer, S. Wagner, E. M. Schraner et al., Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles, J Virol, vol.12, issue.2017, p.91
DOI : 10.1128/jvi.00343-17

URL : https://jvi.asm.org/content/jvi/91/11/e00343-17.full.pdf

F. Zhu, A. H. Wurie, L. Hou, Q. Liang, Y. Li et al., Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebocontrolled, phase 2 trial. The Lancet. 11 févr, vol.389, pp.621-629, 2017.

I. D. Milligan, M. M. Gibani, R. Sewell, E. A. Clutterbuck, D. Campbell et al., Safety and Immunogenicity of Novel Adenovirus Type 26-and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial, JAMA. 19 avr, vol.315, issue.15, pp.1610-1633, 2016.
DOI : 10.1001/jama.2016.4218

URL : https://jamanetwork.com/journals/jama/articlepdf/2514196/jpc160004.pdf

M. D. Tapia, S. O. Sow, K. E. Lyke, F. C. Haidara, F. Diallo et al., Use of ChAd3EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebocontrolled trial, Lancet Infect Dis. janv, vol.16, issue.1, pp.31-42, 2016.

J. E. Ledgerwood, A. D. Dezure, D. A. Stanley, E. E. Coates, L. Novik et al., Chimpanzee Adenovirus Vector Ebola Vaccine, N Engl J Med. 9 mars, vol.376, issue.10, pp.928-966, 2017.
DOI : 10.1056/nejmoa1410863

URL : http://apps.who.int/iris/bitstream/10665/208883/1/ebolasitrep_10Jun2016_eng.pdf?ua=1

, OMS | Les origines de l'épidémie d'Ebola, 2014.

. Disponible,

S. Baize, D. Pannetier, L. Oestereich, T. Rieger, L. Koivogui et al., Emergence of Zaire Ebola Virus Disease in Guinea, N Engl J Med, vol.371, issue.15, pp.1418-1443, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01011799

, OMS | Les facteurs qui ont contribué à la propagation cachée du virus Ebola et empêché son confinement rapide

. Oms-|-guinée, le virus Ebola montre sa ténacité

. Disponible,

. Oms-|-le, Libéria: un pays, et sa capitale, submergés par les cas d'Ebola

O. Leone, une flambée initialement modérée qui s'est finalement révélée être la plus fulgurante

L. 'épidémie-d'ebola-en-chiffres, Update: Épidémie de maladie à virus Ébola-Afrique de l'Ouest, octobre, 2014.

B. P. Bell and . Overview, Control Strategies, and Lessons Learned in the CDC Response to the 2014-2016 Ebola Epidemic. MMWR Suppl, 2016.

. Oms-|-le-succès-des-ripostes-contre-le-virus-ebola-au-nigéria, . Sénégal, and . Au-mali,

R. Afrique, Ebola: géographie, chiffres et histoire de l'épidémie-RFI

, OMS | Feuille de route pour la riposte au virus Ebola: rapports de situation

, Frontières (MSF) MS. Centre de traitement d'Ebola [MSF] by Médecins Sans Frontières (MSF), vol.91

C. , Caisse des Français de l'Etranger

. Disponible,

. Disponible,